If the potential merger between Express Scripts and MedcoHealth passes the antitrust approval process it will be good news for customers, but bad for pharmaceutical companies and drugstores.
This article published with permission from InvestmentU.com.
Express Scripts looks to carry much more weight in future negotiations as it absorbs its largest competition and doubles its market share to approximately 30%. CVS Caremark (NYSE: CVS) would run the next largest PBM with a 15% market share.
Wall Street Journal
The move will generate antitrust attention and will take some time to finalize, but an approved deal would send ripples through the pharmaceutical industry. reported that the two companies process about 35% of all U.S. prescriptions.
Express Scripts and MedcoHealth: The Facts
Here are some notes on the potential Express Scripts—MedcoHealth deal:
What Does This Mean for Investors?
Last month, we talked about how Walgreen Co. (NYSE: WAG) ended its relationship with Express Scripts over a dispute in medication pricing. Express Scripts, which provides nearly 7% of Walgreen’s business, was trying to get the drugstore to lower its margin on medicine.
Walgreen’s declined and decided to look elsewhere for a PBM relationship. Now drugstores like Walgreen’s may have much less choice in who they deal with. Increased clout and size would shrink margins for drugstores like Walgreen Co. and Rite Aid Corp. (NYSE: RAD).
The Wall Street Journal
The merger would also hurt pharmaceutical company margins. reported that MedcoHealth reportedly collected $5.8 billion in rebates from manufacturers. Express Scripts likely collected a similar amount. With combined resources and less competition, these rebates may balloon further. Companies like Pfizer (NYSE: PFE) and Merck (NYSE: MRK) would likely see shrinking profit margins.
Good for Customers, Bad for Business
Express Scripts vies that this merger would be good for the customer. It would allow the company, which serves as a middleman, to have much more clout in negotiations with “Big Pharma” and drugstores. While this may help consumers, it will hurt businesses and ultimately their investors.
If this deal does finalize it may be time to reassess investments in pharmaceutical companies and drugstores and potentially hop on the PBM bandwagon.